Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Miracle Neutralizer warning

This article was originally published in The Tan Sheet

Executive Summary

Canadians are warned against use of Miracle II Miracle Neutralizer "or any health products exported or sold by" the West Monroe, La.-based firm Tedco, Inc., Health Canada announces Aug. 8. The warning was issued because the product, which can be consumed orally or applied topically, "could contain harmful bacteria" such as E. coli. Miracle Neutralizer's intended uses include "heartburn, sunburn, pet and plant health and vegetable cleaning," the agency states. Health Canada issued a recall for the product in May, but is concerned some consumers are unaware of the withdrawal. Tedco has faced trouble in the U.S. as well. The firm received a July 2003 warning letter for claiming its soaps and moisturizing products could treat diseases such as AIDS and cancer (1"The Tan Sheet" Aug. 11, 2003, In Brief)...

You may also be interested in...



Cullinan Changes Tracks, Moving Lymphoma Bispecific Into Autoimmune

The company will discontinue its trial of the CD19-directed bispecific CLN-978 in NHL and develop it in inflammatory diseases, where it could have an edge over CAR-Ts.

Interview: Theradaptive To Enter Clinical Trial For Spinal Fusion Gel

Theradaptive, which makes a device-biologic combination product to help speed bone healing, recently got authorization to start human trials from the US FDA. Medtech Insight spoke to CEO Luis Alvarez about the company’s past, present and future.

US FDA Expects Joint AdComm Briefing Document, Oncology Chief Says

The combined format is the new default for briefing advisory committee members, US FDA Oncology Center of Excellence Director Pazdur declared.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS098536

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel